CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans. (11th October 2018)

• Record Type: Journal Article
• Authors: Chattopadhyay, Niladri; Kanacher, Tobias; Casjens, Manuela; Frechen, Sebastian; Ligges, Sandra; Zimmermann, Torsten; Rottmann, Antje; Ploeger, Bart; Höchel, Joachim; Schultze‐Mosgau, Marcus‐Hillert
• Is Part Of: British journal of clinical pharmacology. Volume 84:Number 12(2018)
• Page Start: 2857
• Page End: 2866
• Publication Date: 2018-10-11
• Subjects: cytochrome P450 -- drug interactions -- optimal design; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.13750
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan. In addition, the effects of rifampicin on the glucuronidation of bilirubin, an endogenous UDP‐glucuronosyltransferase family 1 member A1 (UGT1A1) substrate, were explored. Methods: This was an open‐label, two‐period study in 12 healthy postmenopausal women. Subjects received a single oral dose of vilaprisan 4 mg in each period. In period 2, administration of vilaprisan was preceded and followed by rifampicin 600 mg day –1 . A subtherapeutic dose of midazolam (1 mg) was coadministered with vilaprisan to monitor CYP3A4 induction. Details of the administration and sampling schedule were optimized by means of a physiologically based pharmacokinetic model. Plasma concentrations of vilaprisan, midazolam, and 1′‐ hydroxy‐midazolam were measured and rifampicin‐associated changes in the glucuronidation of bilirubin were determined. Results: As predicted by our model, the coadministration of rifampicin was associated with a substantial decrease in exposure to vilaprisan and midazolam – indicated by the following point estimates (90% confidence intervals) for the area under the plasma concentration–time curve from zero to the time of the last quantifiable concentration ratio with or without rifampicin: 0.040 (0.0325, 0.0505) for vilaprisan and 0.144 (0.117, 0.178) for midazolam. Further, it was associated with an increase in bilirubin glucuronidation, indicating that UGT1A1 was induced. Conclusions: The exposure to vilaprisan was reduced by 96%. Such a reduction is likely to render the drug therapeutically ineffective. Therefore, it is recommended that the use of strong CYP3A4 inducers is avoided when taking vilaprisan.